Sub group analysis and long-term interim analysis are planned in the next few years. The completed and ongoing trials studying cetuximab in the adjuvant treatment of colon cancer are summarized

in Table 1. Pathophysiology of macrometastasis versus find more micrometastasis So why the failure of two classes of biologic agents- anti-VEGF and anti-EGFR- in the adjuvant setting despite success in metastatic disease? One explanation may be the differing pathophysiology of macrometastatic Inhibitors,research,lifescience,medical versus micrometastatic disease. Different genes, pathways and molecules may be required for a cell to establish itself as a metastatic foci (micrometastatic disease) rather than flourish as a metastatic mass. Micrometastasis may simply have different molecular features than macrometastasis and thus respond Inhibitors,research,lifescience,medical differently to biologic agents (36,37). Some have proposed that micrometastasis may actually grow faster than macrometastasis (Gompertz’s principle) (38), making them

more responsive to cytotoxic chemotherapy than to biologic therapies widely thought to be cytostatic (17). The evolution of a tumor with malignant potential to a tumor that actualizes that potential by establishing metastatic foci is complicated. Certainly the ability to create a new blood supply for tumor growth – angiogenesis- is required. Also required is the ability to make the epithelial-mesenchymal transition (39). Cell-cell adherence must initially be reduced Inhibitors,research,lifescience,medical allowing migration and spread Inhibitors,research,lifescience,medical (40) but later cells must have an analogous mesenchymal to epithelial transition to re-gain cell-cell adherence to make a stable metastasis (41). EGFR is thought to have a significant role in the epithelial-mesenchymal transition of metastatic cells (42). The failure of biologic agents in the adjuvant setting supports the theory that micrometastasis behave differently than clinically apparent Inhibitors,research,lifescience,medical foci of metastatic disease. One theory is that micrometastatic disease may develop

early resistance mechanisms to anti-angiogenic therapy such as increased invasiveness (43) or upregulation of pro-angiogenic mechanisms (44). Others hypothesize that tumor cell dormancy develops in the presence of adjuvant therapy, with tumor re-growth occurring once the biologic and chemotherapeutic Phosphatidylinositol diacylglycerol-lyase agents are no longer present (45). Thus the early benefit of anti-VEGF agents seen in some of the adjuvant trials is lost once bevacizumab is discontinued when cells that were quiescent start to proliferate again (46). Some preclinical and animal model data raise concerns that anti-VEGF therapies may actual select for a more aggressive tumor type with enhanced angiogenic capabilities (43,44,46,47). For example, in a mouse lung cancer model, cells treated with anti-VEGF agents exhibited 50-60% regression of tumor vasculature, however returned to pre-treatment vascularization levels with 7 days of removal of the anti-VEGF receptor drug (48). Similarly, Paez-Ribes et al.